Abstract Although tumor stage remains the key determinant of colorectal cancer prognosis and treatment, there is considerable stage-independent variability in clinical outcome. Molecular markers hold promise for explaining variations in clinical behavior, and may identify patient subsets with differential efficacy and survival after adjuvant chemotherapy, which is the standard of care for patients with lymph-nodepositive, i.e., stage III, colon cancer. An increased understanding of the molecular evolution and progression of colorectal cancer has identified two major pathways of tumorigenesis that are characterized by chromosomal instability and by microsatellite instability. Microsatellite instability is a consequence of deficient DNA mismatch repair that is generally due to epigenetic inactivation of MLH1 in tumors that often carry mutations (V600E) in oncogenic BRAF. Activating BRAF V600E and KRAS mutations are mutually exclusive, and in this article, we review the current status of these mutations and the mismatch repair status as prognostic biomarkers in stage III colon cancers.
Introduction
Colorectal cancer (CRC) is the third commonest cancer in men, and its incidence in women is second only to that of breast cancer worldwide [1] . Colorectal carcinogenesis is a multistep process characterized by activation of oncogenes and loss of tumor suppressor genes. Two major pathways include chromosomal instability and less commonly microsatellite instability (MSI), which occurs in approximately 15 % of all CRCs. MSI is a consequence of deficient DNA mismatch repair (MMR) that results in an accumulation of errors within microsatellite regions, producing high mutation rates [2] . Deficient MMR (dMMR) can arise from inheritance of a germline mutation in an MMR gene (MLH1, MSH2, MSH6, PMS2) in approximately 2-3 % of all CRCs cases [3] [4] [5] , causing Lynch syndrome [6] , or more commonly results from epigenetic inactivation of MLH1 in sporadic cases [7] in association with the CpG island methylator phenotype [8] . Highly concordant results have been shown for tumors evaluated by MSI testing, using a PCR-based method, or MMR protein expression by immunohistochemistry [9] . Tumors with loss of an MMR protein are considered to have dMMR, and this term is often used interchangeably with MSI. Sporadic CRCs with MSI are enriched with activating mutations in the BRAF (B-type RAF kinase) oncogene, which encodes a serine/threonine protein kinase and leads to stimulation of the mitogen-activated protein kinase pathway [10] . The BRAF V600E mutation, which consists of a valine to glutamic acid substitution, has an overall frequency of approximately 10 % in CRCs [10, 11] and is mutually exclusive with KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations [12, 13] . The KRAS proto-oncogene encodes a protein that is a member of the GTPase superfamily. A single amino acid substitution is responsible for abrogating the GTPase activity, resulting in a mutation that activates the RAS/RAF signaling pathway. KRAS mutations occur early during colorectal carcinogenesis, and are found in 35-42 % of tumors [12, 13] . KRAS and BRAF V600E mutations predict nonresponse to anti-epidermal growth factor receptor (EGFR) antibody therapy in patients with metastatic CRCs, although only KRAS has been validated [12, 14, 15] .
Disease stage remains the strongest prognostic variable and is the key determinant of patient management. Within a given tumor stage, however, there is considerable variability in prognosis that is likely due to clinicopathological factors, molecular heterogeneity, and/or tumor/host-related immunologic factors. Such variability is particularly evident in lymphnode-positive cancers, i.e., stage III, and those patients with distant metastatic disease, i.e., stage IV. Pathway-related biomarkers hold promise for both prediction and prognosis, although most have not been studied in trials of modern combination chemotherapy regimens. Furthermore, conflicting data have been reported for the prognostic impact of BRAF V600E and KRAS mutations in nonmetastatic disease. In this article, we review the current status of MMR status and KRAS and BRAF V600E mutations as prognostic biomarkers in stage III colon cancer patients.
MMR Status and Clinical Outcome in Stage III Colon Cancer
Patients Treated with 5-Fluorouracil-Based Adjuvant Therapy Multiple studies have shown that patients with dMMR colon cancers have more favorable survival compared with patients with proficient MMR (pMMR) tumors [16] . This observation was confirmed in a large meta-analysis including 32 studies comprising 1,277 MSI cases among a total of 7,642 patients with stage I-IV disease [17] . The analysis included untreated patients, as well as patients treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy. The hazard ratio (HR) for overall survival (OS) associated with dMMR was 0.65 [95 % confidence interval (CI), 0.59-0.71]; benefit persisted when analyses were restricted to patients with stage II or stage III cancers participating in clinical studies [17] .
Although most studies have shown a lack of benefit for 5-FU treatment in dMMR patients [18] [19] [20] [21] [22] , early studies produced variable results, with some showing a survival benefit [23] [24] [25] or even a deleterious effect [26, 27] . This discrepancy is likely due to limited sample size, inclusion of multiple tumor stages, and different 5-FU-based adjuvant regimens [16] . Sargent et al. [27] reported data on 457 stage II and stage III colon cancer patients who were included in five randomized trials evaluating 5-FU-based adjuvant chemotherapy. MSI was shown to be a favorable prognostic marker for the overall population of patients with stage II and stage III colon cancer, as well as a negative predictor of adjuvant 5-FU benefit (Table 1 ). These findings were maintained when the data were pooled with those published in 2001 by Ribic et al. [26] to yield a total of 1,027 stage II and stage III colon cancer patients [27] (Table 1) . In this analysis, MSI was associated with better survival in stage II and III colon cancer, and was a negative predictor of adjuvant 5-FU benefit for stage II and stage III colon cancer, with a suggestion of a detrimental effect in stage II colon cancer. Lack of clinical benefit for 5-FU treatment in MSI tumors is consistent with the findings of preclinical studies where human CRC cell lines with MSI display resistance to 5-FU [28] .
In a study that evaluated 2,141 stage II and stage III colon cancers from 5-FU-based adjuvant therapy trials, patients with dMMR colon cancers were shown to have reduced rates of tumor recurrence, delayed time to recurrence, and improved survival rates compared with patient with pMMR colon cancers [29•] . Furthermore, a subset analysis suggested that the predictive utility of MMR for 5-FU treatment might be different according to the molecular mechanism underlying dMMR/MSI, i.e., MLH1 promoter methylation versus germline MMR gene mutation [ The use of oxaliplatin in combination with adjuvant 5-FU chemotherapy is the current standard of care for stage III colon cancer patients [30] [31] [32] . Preclinical data indicate that MSI tumor cells are sensitive to oxaliplatin despite displaying resistance to 5-FU [33] . To date, however, data examining t h e p r o g n o s t i c / p r e d i c t i v e i m p a c t o f M M R o n chemosensitivity to oxaliplatin-based treatment are very limited [34] [35] [36] [37] . A preliminary clinical study suggested that the addition of oxaliplatin may reverse the 5-FU resistance for dMMR stage III colon cancer [35] . Gavin et al. [38••] [42, 43] . A retrospective analysis of 702 stage III colon cancer patients included in the CALGB 89803 trial showed that dMMR patients (n=96) treated with 5-FU and irinotecan had improved 5-year DFS as compared with pMMR patients (n= 606) (p=0.03). This relationship was not observed among patients treated with 5-FU alone [44] . However, this finding was not confirmed by the analysis of the second study presented by Tejpar et al. [45] . In this retrospective analysis of 1,254 patients included in the PETACC-3 study, Tejpar et al. [45] found that among patients with dMMR tumors, those treated with 5-FU plus irinotecan did not show significantly improved survival compared with patients treated with 5-FU alone.
Patients Receiving Targeted Therapies in an Adjuvant Setting
Given the success of biologic agents in the metastatic setting, such as directed against vascular endothelial growth factor (VEGF) or EGFR, studies were performed to investigate possible beneficial effect of these agents in the adjuvant setting. However, these trials have shown no survival benefit for anti-EGFR or anti-VEGF antibodies combined with chemotherapy in the adjuvant setting [46] [47] [48] . The North Central Cancer Treatment Group (NCCTG) N0147 trial tested the addition of cetuximab to oxaliplatinbased standard adjuvant chemotherapy in the treatment of stage III colon cancer [46] . Because of no effect from adjuvant cetuximab was reported, tumors from both study arms were pooled for the analysis of the prognostic impact of MMR status [49] . Defective MMR was detected in 314 (12 %) of 2,580 colon cancer patients. In this study, MMR status was not prognostic overall for DFS (HR=0.82; 95 % CI, 0.64-1.07; p=0.14). However, favorable DFS was observed for dMMR tumors versus pMMR tumors in the proximal colon (HR= 0.71; 95 % CI, 0.53-0.94; p=0.018) but not in the distal colon (HR=1.71; 95 % CI, 0.99-2.95; p=0.056), with adjustment for KRAS and BRAF V600E mutations [49] . In the NSABP C-08 trial, which showed no benefit for the addition of bevacizumab to FOLFOX therapy [15] , a post hoc analysis showed that patients with dMMR tumors derived a statistically significant survival benefit from the addition of bevacizumab (HR=0.52; 95 % CI, 0.29-0.94; p=0.02) compared with patients with pMMR tumors (HR=1.03; 95 % CI, 0.84-1.27; p=0.78) [50] . The mechanism underlying this interesting finding awaits further study.
Prognostic Impact of KRAS in Patients with Stage III Colon Cancer
The prognostic value of KRAS mutations has been evaluated in several studies in the literature. Most of them are small, retrospective, and heterogeneous and included patients with stage III CRC but also other tumor stages. The results were conflicting: some studies reported no prognostic value [51, 52] , whereas some others suggested a prognostic impact of KRAS mutations [49, 53] or of a single specific KRAS mutation [54] [55] [56] [57] .
To try to clearly define the prognostic value of KRAS mutation in CRC, the RASCAL group developed a collaborative database that includes KRAS mutation data, tumor characteristics, and outcomes. In the first RASCAL study, of 2,721 patients, including 435 stage III CRCs, the rate of KRAS mutation was not different according to the primary tumor site or stage. Results of multivariate analysis (including tumor stage as a covariate) suggested that the presence of a KRAS mutation was associated with shorter failure-free survival (HR=1.25; 95 % CI, 1.10-1.42; p<0.001) and shorter OS (HR=1.22; 95 % CI, 1.07-1.40; p=0.004) [57] . Moreover, subgroups analysis suggested that different KRAS mutations may not have the same prognostic value [57] . In their second publication, the RASCAL group in the RASCAL II study evaluated 4,268 patients, of whom 1,256 had stage III CRCs. They found that the G12V mutation had significantly worse failure-free survival (HR=1.5; 95 % CI, 1.13-1.98; p= 0.0076) and OS (HR=1.45; 95 % CI, 1.07-1.96; p=0.02) in the subgroup of patients with stage III CRC, and in the overall population. All other KRAS mutations had no prognostic value [58] . The RASCAL studies were based on the collection of data from patients included in different studies with variable KRAS mutation assessment. Moreover, the meta-analyses results reported in the RASCAL study are limited by the heterogeneity of patients included and the number of analyses performed.
Prospective randomized clinical trials remain the gold standard to validate the value of putative prognostic biomarkers [59] . In the absence of such data, the alternative approach is to retrospectively analyze putative biomarkers from prospective clinical trials as has been done for the predictive value of KRAS mutations for anti-EGFR antibodies. The prognostic value of KRAS codon 12 and codon 13 mutations has been evaluated retrospectively in four randomized phase III adjuvant trials in patients with stage II and stage III colon cancer: the CKVO 90-11 trial [13, 25, 49, 52] . In three of these studies, a KRAS mutation had no prognostic value [13, 25, 52] , with the exception of the NCCTG N0147 study, where KRAS mutations were independently associated with poorer DFS and OS after adjustment for clinicopathological features and MMR status [49, 60] . In the PETACC-3 trial, significant interactions were found between the presence of a KRAS mutation and tumor site, differentiation grade, age, and MMR status. A KRAS mutation was more frequent in right-sided tumors and well-differentiated tumors in microsatellite-stable CRC [13] . In the subgroup of patients with microsatellite-stable CRC, a KRAS mutation was associated with a slightly worse prognostic value for recurrence-free survival (RFS) (HR=1.29; 95 % CI, 1.03-1.61; p=0.029) and OS (HR= 1.33; 95 % CI, 1.01-1.74; p=0.039) in patients with stage II or stage III CRC. This effect seemed more important in stage II tumors than in stage III tumors [13] . More recently, the prognosis of seven individual KRAS mutations in codon 12 and codon 13 was examined from patients included in the NCCTG N0147 trial, and mutations in both codons were associated with adverse outcome [61] .
Taken together, these data fail to provide consistent evidence for the prognostic impact of KRAS in stage III colon cancer, and the explanation for the discrepant results remains unclear. Most studies evaluated exon 2 KRAS mutations, but the prognostic value of the rare mutations occurring in exon 3 or exon 4 of KRAS has not been evaluated. The predictive value of these rare KRAS mutations for a beneficial effect of anti-EGFR antibodies has recently been demonstrated in metastatic CRC [62, 63] . In all cases, the absence of a beneficial effect of anti-EGFR antibodies in the adjuvant setting and the unresolved queries about its prognostic value do not justify testing for KRAS mutation in patients with stage III CRC in routine clinical practice.
Prognostic Impact of BRAF V600E in Patients with Stage III Colon Cancer
Consistent evidence indicates that BRAF V600E mutations are associated with poor outcome in patients with metastatic CRC compared with wild-type BRAF patients as indicated by significantly shorter progression-free survival and OS [12, 64] . However, the prognostic value of BRAF V600E status in stage II and stage III colon cancer patients treated with adjuvant chemotherapy remains controversial given conflicting data for RFS/DFS, whereas OS data are more consistent (Table 2) [13, 22, 38••, 49, 65, 66] . A combined analysis of data from stage II and stage III colon cancer patients included in the PETACC-3, European Organisation for Research and Treatment of Cancer (EORTC) 40993, and Swiss Group for Clinical Cancer Research (SAKK) 60-00 trials, showed a BRAF V600E mutation frequency of 7.9 % (n=1,217), which was associated with reduced OS (HR=1.78; 95 % CI, 1.15-2.76; p=0.010), but not RFS, in a multivariate analysis [13] . Similarly, the CALGB 89803 trial showed that BRAF V600E mutation, detected in 14.8 % of cancers, was a poor prognostic factor for OS in a multivariate analysis (HR=1.66; 95 % CI, 1.05-2.63; p=0.015), but not for DFS (HR=1.48; 95 % CI, 0.96-1.88) in stage III colon cancer patients (n=506) [66] . The prognostic value of BRAF V600E was also evaluated in the NSABP C-07 and C-08 adjuvant therapy trials [38••] , where the frequency of BRAF V600E mutations in 2,226 patients was 14.2 %. In stage II and stage III colon cancer patients, BRAF V600E was a prognostic factor for OS (HR=1.46; 95 % CI, 1.20-1.79; p=0.0002) but not for RFS (HR=1.02; 95 % CI, 0.82-1.28; p=0.86). The survival after recurrence (SAR) was shortened for patients with BRAF V600E mutations, and this effect was significant on multivariate analysis (HR=2.3; 95 % CI, 1.83-2.95; p < 0.0001). The association of BRAF V600E with poor SAR in this study may potentially explain why BRAF V600E mutations were not prognostic for RFS, but were for OS, and is consistent with the association of BRAF V600E with poor OS in metastatic patients [66, 67] . In contrast to other studies, BRAF V600E mutations were found to be associated with significantly worse DFS [49] and OS [60] rates on multivariable analysis in the NCCTG N0147 trial.
As previously discussed, BRAF V600E mutation is frequently observed in sporadic CRCs with MSI. The prognosis impact of BRAF V600E mutation according the MMR status has been examined in some retrospective analyses of adjuvant studies [38••, 66, 68-71] . Recently, Gavin et al. [38••] . reported the prognostic value of BRAF V600E and MMR status in patients with stage II a n d s t a g e I I I c o l o n c a n c e r s t r e a t e d w i t h fluoropyrimidine-based chemotherapy with or without oxaliplatin with or without bevacizumab. Patients whose tumors had wild-type BRAF and dMMR had the best prognosis (HR=0.55; p=0.0011) compared with patients whose tumors had wild-type BRAF and pMMR. Patient whose tumors had mutated versus wild-type BRAF and pMMR had the worst prognosis (HR=1.58; p=0.0005). Patients with wild-type BRAF/pMMR or BRAF V600E mutation/dMMR tumors had intermediate survival [38••] . In the NCCTG N0147 adjuvant study, the adverse impact of BRAF V600E mutations was limited to pMMR colon cancers [49, 60] . These data suggest that the presence of dMMR may attenuate the adverse prognostic impact of BRAF V600E mutations that are detected in nearly 50 % of sporadic dMMR tumors [10] .
A combined analysis of the predictive role of BRAF V600E mutation alone or combined with MSI status in patients treated in MOSAIC and in the NSAPB C-07 study is in process [31, 72] . This combined analysis aims to evaluate the predictive impact of these two biomarkers for oxaliplatin benefit.
Conclusions
Advances in the molecular characterization of CRCs have identified pathway-based biomarkers that are in current use for detection of hereditary colon cancer, prognostication, and prediction of response to anti-EGFR antibody therapy in advanced disease. Most studies have shown an association of MSI/dMMR with more favorable patient survival in stage II and stage III disease. Furthermore, MSI/dMMR predicts lack of 5-FU benefit in stage II disease, although the data are less clear in stage III disease, including recent studies that included oxaliplatin. BRAF V600E mutations appear to be an adverse prognostic marker in advanced disease, and the association of BRAF V600E with adverse outcome is evident in nodepositive colon cancers, especially for OS. Discrepant results exist for oncogenic mutations in KRAS in nonmetastatic CRC patients in clinical trial cohorts, and although the explanation for different results among studies is not entirely clear, relevant factors include retrospective analyses, potential interactions between biomarkers and chemotherapy agents, and the inherent limitations of cross-trial comparisons. Attempts to validate findings for these biomarkers in independent patient cohorts and to examine pooled datasets that increase the numbers of mutant tumors and outcome events are ongoing. Lastly, studies suggest that combinations of biomarkers or identification of pathway-based molecular subtypes using genomic tools may be informative for prognosis and/or prediction and hold promise for advancing personalized oncology.
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